
CellGeneMedix works in three areas: cancer genomics and longevity genetic testing, which are research programs under development, and COVID-19 diagnostic kits manufactured by our partner, Cellgenemedix, Inc.
Molecular assays that detect treatment-guiding mutations quickly and at low cost.
Five-color multiplex real-time PCR using ARMS primers and probes. Reports KRAS status and BRAF (V600E / V600K) status in colorectal cancer in about four hours on CFX96 and ABI 7500 instruments.
Best Clinical Poster, ASCP 2024 Annual Meeting.
Library workflows for breast cancer gene panels on Illumina short-read and Oxford Nanopore long-read platforms, compared on the same samples.
In development
Testing for healthy adults, so that screening and prevention can start earlier.
Genetic risk for the major diseases of aging: cancer, cardiovascular disease, brain and nervous system, liver disease and kidney disease.
Blood-based markers linked to the hallmarks of aging, such as telomere length, DNA methylation “epigenetic clocks” and inflammation.
Developed during the COVID-19 pandemic and manufactured by Goodgene, Inc. in Korea.
Specimens: nasal, oral and oropharyngeal swabs; bronchoalveolar lavage; nasopharyngeal or oropharyngeal lavage or aspiration.
Steps: RNA extraction (for example, QIAamp Viral RNA Mini Kit), mixing GG reagents with RT-PCR master mix, then real-time PCR on Applied Biosystems 7500, CFX96 Touch, Rotor-Gene Q or LineGene 9600 Plus.
For product information or research collaborations, contact us.
Cancer genomics and longevity assays are for research use only, not for diagnostic use, and are not cleared or approved by the U.S. FDA.